---
title: "Open Orphan PLC (ORPH.L) First volunteer dosed in COVID-19 clinical trial"
publisher: "Share Talk"
author: "sharetalk"
published: "2021-01-11T09:35:11+00:00"
modified: "2021-01-11T09:35:11+00:00"
date: 2021-01-11
canonical: "https://www.share-talk.com/open-orphan-plc-orph-l-first-volunteer-dosed-in-covid-19-clinical-trial/"
category: "Healthcare"
categories: ["Healthcare"]
tags: ["antiviral", "Cathal Friel", "CHIMagents", "clinical respiratory drug", "Codagenix", "COVID-19", "Dengue Fever", "Gregory Stoloff", "hVIVO", "Imutex Ltd", "laboratory", "Malaria", "Open Orphan", "ORPH", "pharmaceutical", "quarantine clinic", "The Lancet", "Vaccine", "virology", "West Nile Virus", "Zika"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1"
format: "news"
language: "en-GB"
---

# Open Orphan PLC (ORPH.L) First volunteer dosed in COVID-19 clinical trial

**Published:** January 11, 2021
**Author:** sharetalk
**Categories:** Healthcare
**Tags:** antiviral, Cathal Friel, CHIMagents, clinical respiratory drug, Codagenix, COVID-19, Dengue Fever, Gregory Stoloff, hVIVO, Imutex Ltd, laboratory, Malaria, Open Orphan, ORPH, pharmaceutical, quarantine clinic, The Lancet, Vaccine, virology, West Nile Virus, Zika
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1)

---

**First volunteer dosed in intran asal COVID-19 vaccine clinical trial**

**Open Orphan plc (AIM: ORPH)**, a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces that the first volunteer has been dosed with the Codagenix Inc. (“Codagenix”) needle free, intranasal COVID-19 vaccine, COVI-VAC. Conducted by hVIVO, part of Open Orphan plc, the Phase I clinical trial of COVI-VAC is being carried out at their facility in the UK. COVI-VAC is a single-dose, intranasal, live attenuated (the entire virus in a weakened form) vaccine against SARS-CoV-2, the virus that causes COVID-19.

Further to the Company’s announcement on 28 July 2020, hVIVO is working in collaboration with US biotech Codagenix to conduct a Phase I study of COVI-VAC. This is a randomised, double-blinded, placebo-controlled dose-escalation study, and will evaluate the safety and tolerability of the single-dose intranasal vaccine candidate in 48 healthy young adult volunteers at hVIVO’s state-of-the-art Quarantine Facility in Whitechapel, London.

The study will also evaluate the vaccine’s ability to provoke an immune response – measuring neutralising antibodies, mucosal immunity in the airway and cellular immunity. COVI-VAC has the potential to address several key logistical challenges to immunisation against SARS-CoV-2 at a global scale. As a single-dose, intranasally-delivered vaccine, COVI-VAC will not require a needle and syringe to be administered, nor ultra-low temperature freezers for storage. COVI-VAC can be manufactured on a large scale and supports ease of administration in a mass vaccination campaign. Codagenix expects to report initial data from the study by mid-2021.

![](https://www.share-talk.com/wp-content/uploads/2020/09/ORPH-300x200.jpg)

**Cathal Friel, Executive Chairman, Open Orphan, commented:** “We are delighted to have been chosen by the New York based Codagenix to run this very important COVID-19 vaccine study in our quarantine clinic in London. This vaccine is one of the first of the next generation COVID-19 vaccines, it is a single dose, needle-free, intranasal, live attenuated COVID-19 virus vaccine. Thus, in our opinion, because it is a live attenuated virus vaccine, COVI-VAC has the potential to give much longer-lasting cellular immunity against COVID-19 than many of the first-generation vaccines.

“Codagenix sought an inpatient facility for the first in human evaluation of COVI-VAC to allow for thorough evaluation of product safety and real-time volunteer monitoring, and our unique state-of-the-art quarantine facility in East London is one of the few facilities in the world suitable to conduct this trial safely and successfully. hVIVO are providing a full-service trial as part of this contract with Codagenix and the team at FluCamp have been responsible for all aspects of trial recruitment for this study through www.FluCamp.com .

“hVIVO is world-recognised for its expertise in evaluation of live viruses in human volunteers and we look forward to a positive outcome.”

**Sybil Tasker, MD, MPH, Chief Medical Officer of Codagenix, said**: “Dosing of the first patients in the Phase 1 clinical trial of COVI-VAC, our single-dose, intranasal, live attenuated vaccine against COVID-19, is an important milestone for Codagenix and the hVIVO team. As a live attenuated vaccine, COVI-VAC has the potential to provide a broader immune response in comparison to other COVID-19 vaccines that target only a portion of the virus, which could prove critical as new variants of SARS-CoV-2 have begun to emerge. Additionally, we believe COVI-VAC can address potential gaps in supplying the global immunization effort against COVID-19, especially in developing countries .”

Interested in becoming a volunteer?

hVIVO recruits many of its volunteers for its challenge study clinical trials through its dedicated volunteer recruitment website, www.flucamp.com . hVIVO welcomes volunteers to take part in our clinical trials under expertly supervised conditions, to further medical research, and help us to take the understanding of respiratory illnesses to a new level. Volunteers are central to the work that we do; our studies focus on testing new treatments on real people, in a safe, controlled, clinical environment.

Further details on all aspects of our volunteer programs including testimonials from previous volunteers can be found at www.flucamp.com .

If you are interested in being contacted and provided with details about future COVID-19 human challenge study research, please leave your contact details at www.UKCovidChallenge.com .

---

**Original URL:** https://www.share-talk.com/open-orphan-plc-orph-l-first-volunteer-dosed-in-covid-19-clinical-trial/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*
